Tovinontrine

Description: Tovinontrine (IMR-687) (IMR-687) is a potent and selective inhibitor of phosphodiesterase-9 (PDE9), designed to target sickle cell disease treatment. It exhibits high efficacy, with IC 50 values of 8.19 nM and 9.99 nM for PDE9A1 and PDE9A2, respectively [1]. Target: PDE. Smiles: C[C@@H]1CN(Cc2ncccn2)C[C@H]1c1cn2c(ncc2c(=O)[nH]1)C1CCOCC1. References: McArthur JG, et al. A novel, highly potent and selective phosphodiesterase-9 inhibitor for the treatment of sickle cell disease. Haematologica. 2020,105(3):623-631.